louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04384809: Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy
Official title: Comparison of Leukocyte-rich Platelet Rich Plasma Injection to Percutaneous Tenotomy in the Treatment of Chronic Common Extensor Tendinopathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Lateral Epicondylitis (Tennis Elbow)
Keywords: common extensor
lateral epicondyle
tennis elbow
Lead sponsor: University Hospitals Cleveland Medical Center
Sponsor class: OTHER
First posted: 2020-05-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Non-blinded, parallel randomized control trial
Primary purpose: TREATMENT

Brief summary: This is a randomized control trial comparing the use of leukocyte rich platelet rich plasma injections to percutaneous tenotomy for the treatment of chronic common extensor tendinopathy.

Detailed description: This is a randomized control trial comparing the use of leukocyte rich platelet rich plasma injections to percutaneous tenotomy for the treatment of chronic common extensor tendinopathy. Patients with a history of common extensor tendinopathy for greater than 3 months, refractory to conservative treatments, are randomized into one of two groups: injection with leukocyte rich platelet rich plasma or percutaneous tenotomy with the Tenex system. Both groups of patients are followed up in clinic at 1 week, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year following the procedure to examine levels of pain or complications following both procedures.

Eligibility criteria: Inclusion Criteria:

* At least 3 months of lateral elbow pain
* Subjectively failed trial of physical therapy and counterbracing
* Identifiable pathology on ultrasound (one or more of the following: thickened or disorganized tendon origin, microtearing, edema, neovascularization

Exclusion Criteria:

* Steroid injection within the last 3 months
* Previous surgery for common extensor tendinopathy
* Current treatment with analgesics
* Pregnant, non-English speaking, or illiterate individuals
* History of anemia
* History of bleeding disorder
* Anticoagulant use
* History of cervical radiculopathy
* Hemoglobin less than 11 grams per deciliter
* Hematocrit less than 33%
* Platelet count outside of normal range of 150-400 x 1000 microliter

Primary outcomes:
measure: Change in pain: visual analogue scale
timeFrame: up to 12 months post-procedure
measure: Change in function
timeFrame: up to 12 months post-procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Cleveland Medical Center
state: Ohio
Study officials:
References:
Clinical trial NCT00614107: Organization in Acute Atrial Fibrillation Post Open Heart Surgery
Official title: Organization in Acute Atrial Fibrillation Post Open Heart Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Atrial Fibrillation post open heart surgery
Lead sponsor: State University of New York - Upstate Medical University
Sponsor class: OTHER
First posted: 2008-02-13
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any person over 18 years having an elective valve, CABG or combination procedure

Brief summary: A form of irregular heart rate called, Atrial Fibrillation (AF) is a major clinical problem. It afflicts about 2 million Americans and is the single largest heart related cause of stroke. However, despite 120 years of speculation and research, the mechanisms that cause AF are poorly understood. Acute AF is also the most common irregular heart rate after open-heart surgery in patients. This is seen in as many as 30% of such patients and often results in a longer hospital stay.

In this study we would like to study the pattern of atrial fibrosis (scar tissue in the heart) and an associated blood marker (a protein called pro-collagen-1) in those patients concurrently having open heart surgery.


Eligibility criteria: Inclusion Criteria:

1. 18 years of age, Male or Female
2. Able to provide consent
3. Cardiac surgery, CABG of Valve replacement or repair.

Exclusion Criteria:

1. If AF terminates within 1 hour of initiation.
2. If the patient undergoes electrical cardioversion and/or receives digitalis within the first hour of inclusion.
3. If the patients and/or their family or the primary caregiver choose to be excluded from the study anytime, even after the initial 24-hour period.
4. If the patient expires within 1 hour of inclusion into the study. -

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Syracuse
country: United States
facility: SUNY Upstate Medical University
state: New York
Study officials:
References:
Clinical trial NCT00222807: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Official title: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Schizoaffective Disorder
Delusional Disorder
Keywords: schizophrenia, psychosis, type 2 diabetes mellitus
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: American Association for Geriatric Psychiatry
name: Janssen Pharmaceuticals
First posted: 2005-09-22
Enrollment: 200
Sex: ALL
Minimum age (years): 14
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with psychosis

Brief summary: This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.

Detailed description: This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.

Eligibility criteria: Inclusion Criteria:

* Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association

Exclusion Criteria:

* Diabetes, type 1 or 2
* Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
* Age above 50 or age below 14

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Ripu D Jindal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00468507: The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application
Official title: The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Trauma
Keywords: CCK release
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2007-05-02
Enrollment: 18
Sex: ALL
Minimum age (years): 45
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Patients undergoing major surgery, trauma and burns are prone to develop an exacerbated inflammatory response, which is potentially lethal to the individual. Recently our group demonstrated that administration of high fat feeding prior to hemorrhagic shock attenuates severe inflammation, gut barrier loss and hepatic damage. High fat feeding releases cholecystokinin in the gut, which stimulates the autonomous nervous system and subsequently activates the efferent vagus nerve. The activated efferent fibers inhibit tissue macrophages via binding of acetylcholine to the alpha7-nicotinergic receptor.

In this study the cholecystokinin release in healthy volunteers is monitored in response to low fat and high fat food products.


Eligibility criteria: Inclusion Criteria:

* Healthy males and females
* 45 \> age \<55

Exclusion Criteria:

* Gastrointestinal diseases
* Inflammatory conditions

Primary outcomes:
measure: CCK-release
timeFrame: two hours
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: University Maastricht
state: Limburg
Study officials:
affiliation: Maastricht University Medical Center
name: Jan-Willem Greve, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00209807: Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
Official title: Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Major Depression
Pain
Abdominal Pain
Keywords: major depression
pain
escitalopram
reboxetine
visceral sensitivity
somatic sensitivity
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints. Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main aim of this study is to compare somatic and visceral sensitivity between healthy people and pateints with MDD. These two sensitivities will be assessed by the 2 following tests: standardized rectal distension and Transdermal transcutaneous electric nerve stimulation. Thereafter, patients with MDD will be randomly allocated to escitalopram or reboxetine. After 6 weeks of treatment, somatic and visceral sensitivity will be reassessed.


Eligibility criteria: Inclusion Criteria:

* MDD according with DSM-IV-TR
* Hamilton depression scale \> 21

Exclusion Criteria:

* history of gastrointestinal illness
* history of escitalopram, citalopram or reboxetine allergy.
* history of escitalopram, citalopram or reboxetine resistant depression.
* other axis I psychiatric disorder.
* a punctuation \> 2 on the suicide item of the Ham-D.
* history of ECT during the past 6 months.
* pharmacological failure of the present depressive episode.
* pregnancy or nursing.
* treatment with drugs that may interact with study medication.

Primary outcomes:
measure: rectal distension Transcutaneous Electrical Neuro-Stimulation
timeFrame: 1-7 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Universitari vall d'Hebron
state: Catalonia
Study officials:
affiliation: Hospital Universitari Vall d'Hebron Research Institute
name: Casas Miguel, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03455907: Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Official title: Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthralgia
Keywords: Bevacizumab
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2018-03-07
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated with Bevacizumab for Lung, ovarian or colorectal cancers.

Brief summary: Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.


Eligibility criteria: Inclusion Criteria:

* Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
* Male or female (aged ≥18 years old)
* Performance Status (PS) between 0 and 2
* Expected life\> 3 months
* Ability to answer a self-questionnaire
* Obtaining the non-opposition of patient participation

Exclusion Criteria:

* Pregnant or lactating woman
* Rapid evolution of neoplastic pathology
* Major cognitive disorders that do not allow filling of the self-questionnaire
* Impossibility to submit to medical monitoring for social, psychological or geographical reasons
* Patients under guardianship or curatorship

Primary outcomes:
measure: Frequency of arthralgia
timeFrame: At 6 months
Secondary outcomes:
measure: correlation between global cancer response and occurrence of arthralgia
timeFrame: baseline, at 3 months, at 6 months
measure: auto questionnaire specific to the study
timeFrame: Baseline at 3 months, at 6 months
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lille
country: France
facility: Hôpital Huriez. CHRU
Study officials:
affiliation: University Hospital, Lille
name: Marie-Hélène Viellard, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vauleon E, Behal H, Lebellec L, Desbarbieux R, Baldacci S, Simon N, Pannier D, Vieillard MH, Turpin A. Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study. Cancer Chemother Pharmacol. 2021 Apr;87(4):533-541. doi: 10.1007/s00280-020-04226-6. Epub 2021 Jan 12.
Clinical trial NCT01990807: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Official title: Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome, Ph^1^, Absent
B-cell Childhood Acute Lymphoblastic Leukemia
Keywords: high risk
Philadelphia Chromosome absent
Childhood acute lymphoblastic leukemia
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2013-11-21
Enrollment: 20
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%. In recent years, Tyrosine Kinase Inhibitor(TKI) has improved outcome of Philadelphia chromosome positive (Ph+)ALL . But in some high risk groups, The prognosis of patients is still very bad and the relapse rate is high. Clearly, new therapies are urgently needed to prevent and /or treat relapsed ALL.

Detailed description: 1. The prognosis of childhood acute lymphoblastic leukemia(ALL) has been increased.
2. Tyrosine Kinase Inhibitor(TKI) has improved Philadelphia chromosome positive (Ph+)ALL treatment outcome.
3. The prognosis of high-risk childhood ALL except for Philadelphia chromosome positive (Ph+)ALL is very bad.

Eligibility criteria: Inclusion Criteria:

Children with high-risk ALL Children lower than 18years old

Exclusion Criteria:

Bcr/Abl(+) Children with middle-risk or standard-risk ALL

Primary outcomes:
measure: The event free survival of high risk ALL
timeFrame: 2 years
Secondary outcomes:
measure: The relapsed rate, death, overall survival
timeFrame: 2 years
Other outcomes:
measure: infection rate
timeFrame: 2 years
Locations:
city: Tianjin
country: China
facility: Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Scienses
state: Tianjin
Study officials:
affiliation: Chinese Academy of Medical Sciences
name: Xiaofan Zhu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00368407: Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck
Official title: Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vitiligo
Keywords: 308-nm excimer laser
vitiligo
Lead sponsor: Air Force Military Medical University, China
Sponsor class: OTHER
First posted: 2006-08-24
Sex: ALL
Minimum age (years): 2
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: To determine the optimal treatment frequency of 308-nm excimer laser for vitiligo and identify the key clinical variable(s) associated with the treatment efficiency under the optimal treatment frequency.

Prospective, randomized, comparative study among groups of vitiligo patients treated with 308-nm excimer laser, with the limitation of no follow-up.

Detailed description: Vitiligo patients were treated with 308-nm excimer laser for 20 sessions at different frequencies (0.5×, 1.0×, 2.0× and 3.0× weekly). Treatment protocols adapted the dose to the lesions and not to the minimal erythemal dose. Treatment efficacy was blindly evaluated by 2 independent physicians. Re-pigmentation rate was graded on a 6-point scale. The onset of re-pigmentation of vitiligo lesions was evaluated after 5 treatment sessions. The differences between Group 0.5×, 1.0×, 2.0× and 3.0× linking different clinical variables were assessed.

Eligibility criteria: Inclusion Criteria:

* older than 2 years, stable vitiliginous patches during the past 3 months with surfaces of at least 4cm2, and an understanding of all information given by signing a written consent form.

Exclusion Criteria:

* pregnant or breastfeeding women; personal history of a hypertrophic scar, skin cancer; taking immunosuppressive or photosensitizing drugs and undergoing phototherapy during the past 3 months.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Department of dermatology, Xijing Hospital
state: SHANNXI
Study officials:
affiliation: Ddepartment of Dermatology
name: gao tianwen, MD,PHD
role: STUDY_DIRECTOR
References:
citation: Hofer A, Hassan AS, Legat FJ, Kerl H, Wolf P. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol. 2005 May;152(5):981-5. doi: 10.1111/j.1365-2133.2004.06321.x.
Clinical trial NCT06990607: Compare PPV With and Without Silicone Oil in Managing Postoperative Endophthalmitis
Official title: Pars Plana Vitrectomy With Silicone Oil Versus Pars Plana Vitrectomy Alone in the Management of Postoperative Endophthalmitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endophthalmitis Following Cataract Surgery
Keywords: Postoperative endophthalmitis
pars plana vitrectomy
silicone oil
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparing PPV with and without silicone oil in managing postoperative endophthalmitis

Detailed description: The objective of this study is to compare the outcomes of PPV with silicone oil tamponade to PPV alone in patients with postoperative endophthalmitis by assessing visual acuity, and postoperative complications such as rhegmatogenous retinal detachment (RRD).

Eligibility criteria: Inclusion Criteria:

* adult patients (≥ 18 years) presenting with clinical manifestations of endophthalmitis after cataract surgery

Exclusion Criteria:

* patients with concurrent ocular or systemic conditions that could potentially confound study outcomes, such as active retinal diseases unrelated to endophthalmitis
* pre-existing poor visual prognosis due to conditions like advanced glaucoma or macular degeneration, or prior ocular surgery affecting the study

Primary outcomes:
measure: visual acuity, with best-corrected visual acuity (BCVA) recorded using LogMAR
timeFrame: 1, 2, 4, and 12 weeks postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University
Study officials:
References: